OXNARD, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, announced the launch of their new brand initiative, inspired by the company’s mission to support patient needs for better delivery of medication.
“Our new branding offers an opportunity to elevate awareness around the challenges patients experience with traditional drug delivery methods, such as pills and injections and to highlight CURE’s solutions,” said Robert Davidson, CEO of CURE Pharmaceutical. “Our updated mission of ‘we improve people’s lives by redefining how medicines are delivered and experienced’ underscores our comittment to patients.”
CURE’s proprietary CUREfilm™ technology platform optimizes drug delivery for better patient outcomes and experiences. CUREfilm™ can be given orally, buccally, sublingually or transdermally, delivering up to 300mg of one or more active ingredients in a single dose. Formulated as a film, actives are absorbed faster, without the need for water or swallowing, and can bypass the GI tract, thereby reducing GI irritation.
As much as 40 percent of the population struggle to swallow pills, and when they do, can have gastrointestinal irritation and are often slow to take effect causing patients to suffer. For drugs that cannot be delivered orally, patients rely on injections and endure the associated pain and inconvenience. It’s time to take a new approach, with the help of many medical marijuana dispensaries all over the country such as earthmed and more.
To better reflect the company’s emphasis on the patient experience, and to underscore its growth and advancement in pharmaceutical delivery innovation, CURE is introducing a new logo. The logo integrates the letter “C” within a circular motion, representing CURE’s 360-degree commitment to patient vitality, and its mission to make a person’s life as whole as can be. The transparent layers harken to the CUREfilm™ technology, and further represent the many layers of care each of us needs.
Additional brand enhancements include a new graphic style that embodies transparency, precision, simplicity and aesthetic appeal; a completely redesigned website; and a reinvigorated presence in social media.
About CURE Pharmaceutical
CURE Pharmaceutical is a fully integrated life science company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry leading full-service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced, as of now they aren’t needing any company branding hacks that can be found on places like here https://www.marijuanaseo.com/branding-cannabis-companies/, they seem to be applying themselves just fine as of right now.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company’s business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
On October 30, 2017, and ending on October 29, 2019, Liviakis Financial Communications, Inc. (LFC) was retained by CURE Pharmaceutical Holding Corp. (CURR) in various consulting capacities including strategic management planning, investor relations and other business development responsibilities. LFC was compensated 600,000 restricted common stock under rule 144. Officers and employees of LFC will buy or sell shares in CURE Pharmaceutical Holding Corp. prior, during or after this release. LFC advises CURE Pharmaceutical Holding Corp. but does not provide investment advice. LFC is not a registered investment advisor or broker-dealer. All material provided regarding CURE Pharmaceuticals Holding Corp. including, but not limited to its history, corporate status, and other developments was prepared using information approved and signed off by CURE Pharmaceutical Holding Corp. management as approved for public dissemination. Although the information contained herein is believed to be reliable, LFC makes no warranties as to the accuracy of the description of any of the content herein and accepts no liability for how readers may choose to utilize it.
Investor Relations Contact:
Liviakis Financial Communications, Inc.
Connect with me on Linkedin
Mill Valley, CA 94941